Iambic Therapeutics, Inc. IAM
IPO
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Net Income | -25.06M | -25.06M | |||
| Total Depreciation and Amortization | 349.00K | 349.00K | |||
| Total Amortization of Deferred Charges | -- | -- | |||
| Total Other Non-Cash Items | 1.54M | 1.54M | |||
| Change in Net Operating Assets | 10.74M | 10.74M | |||
| Cash from Operations | -12.43M | -12.43M | |||
| Capital Expenditure | -968.50K | -968.50K | |||
| Sale of Property, Plant, and Equipment | -- | -- | |||
| Cash Acquisitions | -- | -- | |||
| Divestitures | -- | -- | |||
| Other Investing Activities | -- | -- | |||
| Cash from Investing | -968.50K | -968.50K | |||
| Total Debt Issued | -- | -- | |||
| Total Debt Repaid | -25.00K | -25.00K | |||
| Issuance of Common Stock | 1.01M | 1.01M | |||
| Repurchase of Common Stock | -- | -- | |||
| Issuance of Preferred Stock | 26.35M | 26.35M | |||
| Repurchase of Preferred Stock | -- | -- | |||
| Total Dividends Paid | -- | -- | |||
| Other Financing Activities | -- | -- | |||
| Cash from Financing | 27.34M | 27.34M | |||
| Foreign Exchange rate Adjustments | 5.50K | 5.50K | |||
| Miscellaneous Cash Flow Adjustments | -- | -- | |||
| Net Change in Cash | 13.95M | 13.95M | |||